Article Figures & Data
Figures
- Figure 1.
Design of the SINGLE Study
ABC/3TC, abacavir/lamivudine; ART, antiretroviral therapy; c/mL, copies per milliliter; DTG, dolutegravir; EFV/TDF/FTC, efavirenz/tenofovir/emtricitabine; HIV, human immunodeficiency virus; HLA-B, major histocompatibility complex, class 1, B57.1
Reproduced with permission from K Pappa, PharmD.
- Figure 2.
HIV-1 RNA Results at Week 144
ABC/3TC, abacavir/lamivudine; DTG, dolutegravir; EFV/TDF/FTC, efavirenz/tenofovir/emtricitabine; HIV, human immunodeficiency virus; W48, week 48; W96, week 96; W144, week 144.
Reproduced with permission from K Pappa, PharmD.
Tables
Tools
Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naïve Patients with HIV
Permalink:
Table of contents
Cited By...
- No citing articles found.